Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Raw Materials powder Mitiglinide calcium dihydrate
Product Overview:
mitiglinidecalcium calcium (mitiglinidecalcium), chemically known as (2S) -2-benzyl-3 -(cis-hexahydro2-isodihydroindolyl carbonyl) calcium propionate dihydrate, is clinically used to treat type 2 diabetes mellitus. It was developed by Japan's Kissei Pharmaceutical Company and was first marketed in Japan in May 2004.
Raw Materials powder Mitiglinide calcium dihydrate Attributes
CAS:207844-01-7
MF:C38H52CaN2O8
MW:704.91
EINECS:1308068-626-2
Specification: 99% min Mitiglinide calcium dihydrate powder
Sample:Mitiglinide calcium dihydrate powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Raw Materials powder Mitiglinide calcium dihydrate Details
Mitiglinide calcium dihydrate powder Usage and Synthesis.
Calcium miglinide is the third megligliride after repaglinide and nateglinide. It is an ATP-dependent potassium channel blocker and a derivative of phenylalanine. Its mechanism of action is similar to that of sulfonylureas, but it takes effect faster and has a short half-life. It can not only help reduce postprandial blood sugar in diabetic patients, but also avoid hypoglycemia caused by continuous hypoglycemia. It has the reputation of "external pancreas".
Uses of Mitiglinide calcium dihydrate.
Improvement of postprandial hyperglycemia in patients with type 2 diabetes (limited to patients who cannot effectively control blood glucose through diet and exercise therapy or patients who cannot effectively control blood glucose after adding α-glucosidase inhibitors to diet and exercise therapy).
In vivo study of Mitiglinide calcium dihydrate.
Glinide hypoglycemic agents have the characteristics of rapid, strong and short-term effect, avoiding the occurrence of adverse reactions such as hypoglycemia, and there is no adverse reactions of α-glycosidase inhibitors in the gastrointestinal tract, so it is a more competitive postpranational blood glucose regulator. Calcium miglinide can stimulate the pancreas to secrete insulin quickly and briefly only at the time of eating, and the effect is fast and the effect lasts for a short time. Traditional oral diabetes drugs continue to stimulate insulin secretion, and excessive stimulation, especially between meals, often make patients feel hungry, and even encourage patients to take snacks between meals when using sulfonyl pulse drugs, so that excessive insulin metabolism. This extra eating causes patients to gain weight, and they are often obese to begin with.
Product method of Bulk Mitiglinide calcium dihydrate.